You state in the Coding preventive Medicine section: If the patient is not necessarily obese or does not receive nutrition-specific counseling, look to 99401-99404 and 99411-99412
The patient characteristics have been previously reported (Lin et al, 2022)
Additionally, it supports metabolic health, advancing blood sugar, cholesterol, and blood pressure
JAMA 327, 23342347
The complete list of substances being removed from Category 2 is as follows: BPC-157 Cathelicidin LL-37 Dihexa Acetate Emideltide (DSIP) Epitalon GHK-Cu (for injectable routes of administration) KPV Mechano Growth Factor, Pegylated (PEG-MGF) Melanotan II MOTs-C Semax (heptapeptide) Thymosin Beta-4, Fragment (LKKTETQ) (TB-500) Of these, the substances not scheduled for consideration at the upcoming meeting in July (Cathelicidin LL-37, Dihexa Acetate, GHK-Cu (injectable routes of administration), Mechano Growth Factor Pegylated (PEG-MGF), and Melanotan II) are slated for separate PCAC consultation before the end of February 2027